CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations
BackgroundAfatinib is a potent, irreversible second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor which has demonstrated efficacy in advanced non-small cell lung cancer (NSCLC) patients harboring either common or uncommon EGFR mutations. However, data on its activity a...
Zapisane w:
| Główni autorzy: | , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Frontiers Media S.A.
2023-02-01
|
| Seria: | Frontiers in Oncology |
| Hasła przedmiotowe: | |
| Dostęp online: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1094195/full |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|